Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunovantIMVT +0.36%29 Operating Cash Flow per Share is $-2.17 as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,134 Biotechnology companies, Immunovant ranks worse than 83.16% on this metric.
Immunovant's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.61.
Immunovant's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.17.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -13.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -22.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Immunovant's Operating Cash Flow per Share or its related term are showing as below:
IMVT'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -36.9 Med: -15.65 Max: -7.4
Current: -13.5
During the past 8 years, Immunovant's highest 3-Year average Operating Cash Flow per Share Growth Rate was -7.40% per year. The lowest was -36.90% per year. And the median was -15.65% per year.
IMVT's 3-Year OCF Growth Rate is ranked worse than 83.16% of 1134
companies
in the Biotechnology industry
Industry Median: 17
vs IMVT: -13.50
Immunovant Operating Cash Flow per Share Related Terms
Immunovant Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Immunovant's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMVT vs IBRX, TGTX, PCVX: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Immunovant's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovant Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunovant's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Immunovant's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-2.17 mean?
Immunovant (IMVT) has a Operating Cash Flow per Share of $-2.17 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Immunovant and its competitors. According to the industry distribution chart, Immunovant ranks #943 out of 1134 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Immunovant's Operating Cash Flow per Share too high?
Immunovant's current Operating Cash Flow per Share is $-2.17. Based on the distribution chart, Immunovant ranks #943 out of 1134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's Operating Cash Flow per Share compare to IBRX and TGTX?
According to the Biotechnology industry distribution chart, Immunovant ranks #943 out of 1134 companies for Operating Cash Flow per Share. This places Immunovant in the lower half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,134 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Immunovant and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovant's current Operating Cash Flow per Share is $-2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current Operating Cash Flow per Share of $-2.17. The current Operating Cash Flow per Share is $-2.17. Immunovant's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Immunovant (IMVT), the current Operating Cash Flow per Share is $-2.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score
Get the complete analysis for IMVT
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMVT has been successfully added to your 
